Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Prog Retin Eye Res ; 29(2): 95-112, 2010 Mar.
Article in English | MEDLINE | ID: mdl-19961953

ABSTRACT

During the past ten years, dramatic advances have been made in unraveling the biological bases of age-related macular degeneration (AMD), the most common cause of irreversible blindness in western populations. In that timeframe, two distinct lines of evidence emerged which implicated chronic local inflammation and activation of the complement cascade in AMD pathogenesis. First, a number of complement system proteins, complement activators, and complement regulatory proteins were identified as molecular constituents of drusen, the hallmark extracellular deposits associated with early AMD. Subsequently, genetic studies revealed highly significant statistical associations between AMD and variants of several complement pathway-associated genes including: Complement factor H (CFH), complement factor H-related 1 and 3 (CFHR1 and CFHR3), complement factor B (CFB), complement component 2 (C2), and complement component 3 (C3). In this article, we revisit our original hypothesis that chronic local inflammatory and immune-mediated events at the level of Bruch's membrane play critical roles in drusen biogenesis and, by extension, in the pathobiology of AMD. Secondly, we report the results of a new screening for additional AMD-associated polymorphisms in a battery of 63 complement-related genes. Third, we identify and characterize the local complement system in the RPE-choroid complex - thus adding a new dimension of biological complexity to the role of the complement system in ocular aging and AMD. Finally, we evaluate the most salient, recent evidence that bears directly on the role of complement in AMD pathogenesis and progression. Collectively, these recent findings strongly re-affirm the importance of the complement system in AMD. They lay the groundwork for further studies that may lead to the identification of a transcriptional disease signature of AMD, and hasten the development of new therapeutic approaches that will restore the complement-modulating activity that appears to be compromised in genetically susceptible individuals.


Subject(s)
Aging/physiology , Complement System Proteins/physiology , Macular Degeneration/metabolism , Choroid/metabolism , Gene Expression , Humans , Macular Degeneration/genetics , Polymorphism, Single Nucleotide , Retinal Pigment Epithelium/metabolism
2.
J Immunol ; 178(6): 3831-6, 2007 Mar 15.
Article in English | MEDLINE | ID: mdl-17339482

ABSTRACT

Complement factor H (FH) is an important regulator of the alternative complement pathway. The Y402H polymorphism within the seventh short consensus repeat of FH was recently shown to be associated with age-related macular degeneration, the most common cause of irreversible blindness in the Western world. We examined the effects of this polymorphism on various FH functions. FH purified from sera of age-related macular degeneration patients homozygous for the FH(402H) variant showed a significantly reduced binding to C-reactive protein (CRP), an acute phase protein, as compared with FH derived from unaffected controls homozygous for the FH(402Y) variant. Strongly reduced binding to CRP was also observed with a recombinant fragment of FH (short consensus repeat 5-7) containing the same amino acid change. Because the interaction of CRP and FH promotes complement-mediated clearance of cellular debris in a noninflammatory fashion, we propose that the reduced binding of FH(402H) to CRP could lead to an impaired targeting of FH to cellular debris and a reduction in debris clearance and enhanced inflammation along the macular retinal pigmented epithelium-choroid interface in individuals with age-related macular degeneration.


Subject(s)
C-Reactive Protein/metabolism , Complement Factor H/metabolism , Macular Degeneration/genetics , Polymorphism, Genetic , Aged , Aged, 80 and over , C-Reactive Protein/genetics , Complement Factor H/genetics , Complement Factor H/isolation & purification , Female , Homozygote , Humans , Inflammation/genetics , Inflammation/metabolism , Macular Degeneration/metabolism , Macular Degeneration/pathology , Male , Middle Aged , Pigment Epithelium of Eye/metabolism , Pigment Epithelium of Eye/pathology , Protein Binding/genetics , Retina/metabolism , Retina/pathology
3.
Retina ; 26(3): 262-9, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16508424

ABSTRACT

PURPOSE: Intravitreal bevacizumab (Avastin; Genentech Inc., San Francisco, CA) is a new treatment for age-related macular degeneration. The aim of this study was to evaluate retinal penetration and toxicity of bevacizumab. METHODS: Ten albino rabbits were injected intravitreally with 0.1 mL (2.5 mg) of Avastin into one eye and 0.1 mL saline into the fellow eye. The electroretinogram (ERG) was recorded after 3 hours, 3 days, and 1, 2, and 4 weeks. The visual evoked potential (VEP) was recorded after 4 weeks. Confocal immunohistochemistry was used to assess retinal penetration. RESULTS: The ERG responses of the control and experimental eyes were similar in amplitude and pattern throughout the follow-up period. The flash VEP responses of the experimental eyes were of normal pattern and amplitude and did not differ from those recorded by stimulation of the control eye alone. Full thickness retinal penetration was present at 24 hours and was essentially absent at 4 weeks. CONCLUSIONS: Bevacizumab was found to be nontoxic to the retina of rabbits based on electrophysiologic studies. Full thickness retinal penetration may explain observed clinical effects of intravitreal bevacizumab. Although it is difficult to directly extrapolate to humans, our study supports the safe use of intravitreal bevacizumab injection.


Subject(s)
Antibodies, Monoclonal/pharmacokinetics , Antibodies, Monoclonal/toxicity , Retina/metabolism , Animals , Antibodies, Monoclonal, Humanized , Bevacizumab , Drug Evaluation, Preclinical , Electroretinography/drug effects , Evoked Potentials, Visual/drug effects , Fluorescent Antibody Technique, Indirect , Injections , Rabbits , Retina/drug effects , Retina/physiology , Retinal Ganglion Cells/drug effects , Retinal Ganglion Cells/metabolism , Vascular Endothelial Growth Factor A/immunology , Vitreous Body
4.
Invest Ophthalmol Vis Sci ; 46(12): 4788-95, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16303980

ABSTRACT

PURPOSE: Drusen are risk factors for age-related macular degeneration and have been shown to negatively impact cells of the RPE and retina. In this study, the effects of drusen on the synaptic machinery of retinal photoreceptors are investigated. METHODS: Human donor eye tissue containing retina, RPE, and choroid was processed for confocal immunofluorescence microscopy, laser capture microdissection, and light and electron microscopy. Tissue sections were immunostained with a panel of antibodies to synapse-associated proteins. Populations of photoreceptors over drusen and normal populations of photoreceptors were microdissected from fresh frozen tissue, RNA was purified, and quantitative PCR was performed to compare relative levels of gene expression. RESULTS: The number of photoreceptor synaptic terminals is reduced in regions of the outer plexiform layer over drusen, synaptic proteins are mislocalized in photoreceptor cells, and synaptic terminals are often observed within the outer nuclear layer. Photoreceptors over drusen also increase expression of the stress response proteins apolipoprotein E and alphaB-crystallin. Abnormal immunolabeling patterns are not restricted to photoreceptors directly over drusen but are also observed in cells flanking drusen. Gene expression analysis confirms reductions in the expression of genes coding for synapse-associated proteins and signal transduction proteins and increases in the expression of apolipoprotein E and alphaB-crystallingene transcripts. Ultrastructural analysis of photoreceptor synaptic terminals over drusen reveals significant abnormalities, and cell counts show a reduction in photoreceptor density directly over, and lateral to, drusen of all sizes. CONCLUSIONS: Photoreceptors overlying and flanking drusen exhibit morphologic and biochemical signs of degeneration. The expression of synapse-associated proteins decreases in photoreceptor synaptic terminals, whereas the expression of stress-response proteins increases. Reductions in photoreceptor cell densities over, and flanking, drusen suggest that these degenerative effects eventually result in the death of photoreceptors.


Subject(s)
Gene Expression Regulation , Macular Degeneration/pathology , Nerve Tissue Proteins/genetics , Photoreceptor Cells, Vertebrate/pathology , Presynaptic Terminals/pathology , Retinal Drusen/pathology , Aged , Aged, 80 and over , Apolipoproteins E/genetics , Apolipoproteins E/metabolism , Cell Count , Fluorescent Antibody Technique, Indirect , Humans , Macular Degeneration/genetics , Macular Degeneration/metabolism , Microscopy, Confocal , Microscopy, Electron , Middle Aged , Nerve Tissue Proteins/metabolism , Paraffin Embedding , Photoreceptor Cells, Vertebrate/metabolism , Presynaptic Terminals/metabolism , Retinal Drusen/genetics , Retinal Drusen/metabolism , Reverse Transcriptase Polymerase Chain Reaction , beta-Crystallin A Chain/genetics , beta-Crystallin A Chain/metabolism
5.
Invest Ophthalmol Vis Sci ; 44(10): 4481-8, 2003 Oct.
Article in English | MEDLINE | ID: mdl-14507896

ABSTRACT

PURPOSE: Drusen are variably sized extracellular deposits that form between the retinal pigmented epithelium (RPE) and Bruch's membrane. They are commonly found in aged eyes, however, numerous and/or confluent drusen are a significant risk factor for age-related macular degeneration. The purpose of this study was to investigate the impact of drusen on overlying cells of the retina. METHODS: Tissue containing retina and RPE/choroid was dissected from human donor eyes, embedded in agarose, and sectioned at 100 micro m using a vibratome. Sections were immunostained with a panel of antibodies that labeled glial cells, first-, second-, and third-order retinal neurons and processed for confocal microscopy. RESULTS: Retinal cells that overlie both soft and hard drusen exhibited numerous structural and molecular abnormalities. Normally detectable only in the outer segments of rod photoreceptors, rod opsin immunolabeling was also observed in the inner segment, cell body, axon, and axon terminal of photoreceptors that overlie drusen. Labeling with this antibody also revealed the deflection and shortening of rod inner and outer segments. Cone photoreceptors displayed similar structural abnormalities, as well as a decrease in cone opsin immunoreactivity. Drusen-associated abnormalities in the synaptic terminals of photoreceptor cells were also observed. In addition, an increase in intermediate filament protein immunoreactivity (vimentin and glial fibrillary acidic protein) was observed within Müller glial cells in areas of retina overlying drusen. Both soft and hard drusen were associated with a similar spectrum of effects in both macular and extramacular regions. Second- and third-order neurons, including bipolar, horizontal, amacrine, and ganglion cells all appeared unaffected. The structural and molecular abnormalities observed in photoreceptors and Müller glial cells were confined to retinal regions directly overlying and immediately adjacent to drusen; more distant retinal regions appeared unperturbed. Remarkably, significant abnormalities were observed over small subclinical drusen. CONCLUSIONS: Retinal cells overlying both soft and hard drusen exhibit structural and molecular abnormalities indicative of photoreceptor degeneration and Müller glial activation. These abnormalities resemble the degenerative effects common to many forms of retinal degeneration, but are confined to areas directly overlying drusen. This suggests that photoreceptor cell function is compromised as a consequence of drusen formation.


Subject(s)
Pigment Epithelium of Eye/pathology , Retina/pathology , Retinal Drusen/pathology , Aged , Aged, 80 and over , Axons/metabolism , Axons/pathology , Choroid/metabolism , Choroid/pathology , Fluorescent Antibody Technique, Indirect , Glial Fibrillary Acidic Protein/metabolism , Humans , Middle Aged , Neuroglia/metabolism , Neuroglia/pathology , Photoreceptor Cells, Vertebrate/metabolism , Photoreceptor Cells, Vertebrate/pathology , Pigment Epithelium of Eye/metabolism , Retina/metabolism , Retinal Drusen/metabolism , Rod Opsins/metabolism , Vimentin/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...